FMS-like tyrosine kinase 3 (FLT3) Mutation

 Specimen Collection, Storage, and Shipping

Test Information:
FLT3 internal tandem duplication (ITD) mutations and FLT3 tyrosine kinase domain (TKD) mutations have been reported in about 30% and 7% of AML patients, respectively. Identification of FLT3 mutations provides prognostic information and may play a pivotal role in determining appropriate treatment options for AML patients. A high FLT3 ITD mutant:wild-type allelic ratio has been correlated with a distinctly poor outcome in some studies, and may account for the different therapeutic response in patients. Patients with high ITD-allelic ratios (>0.4) have significantly higher rates of relapse and poor outcome compared to patients with lower ITD-allelic ratios.

This assay uses multiplexed PCR followed by restriction enzyme digestion and capillary electrophoresis, which is the accepted standard procedure for FLT3 detection. All ITD and TKD mutations above the assay’s limit of detection are reported. ITD mutations are quantified if ≥ 0.05 allelic ratio (mutant to wild-type area).

Requisition Code:
FMS-like tyrosine kinase 3 (FLT3) Mutation
FMS-like tyrosine kinase 3 (FLT3) Mutation STAT

CPT Code: 81245; 81246; G0452-26 (x2)

Turn Around Time:
FLT3: 5-7 days
FLT3 STAT: 2-3 days

Specimen Requirements
Collect: Peripheral blood: 2-5 mL in EDTA (purple top) tube
Bone marrow: 2-5 mL in ACD (yellow tube) or EDTA (purple top) tube
Storage: Room temperature
Transport: See Standard Shipping Procedures


  1. Murphy KM, et al. Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Change Reaction and Capillary Electrophoresis Assay. J Mol Diagn. 2003 May;5(2):96-102.

  2. Schlenk RF, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation. Blood. 2014; 124(23):344-3449.